Status: Recruiting
Pelvic Ultra-Hypofractionated Adjuvant Radiotherapy for Endometrial Cancer (PURE-cohort)
The PURE trial is a prospective multicenter phase II study evaluating the safety and feasibility of ultra-hypofractionated adjuvant pelvic radiotherapy in patients with high-intermediate-risk and high-risk endometrial cancer following surgery. The study investigates a treatment regimen consisting of 27.5 Gy delivered in five fractions using modern image-guided IMRT/VMAT techniques. The primary objective is to assess acute gastrointestinal and genitourinary toxicity according to CTCAE version 5.0.
Participants needed: 50
Trial details
Age: 18-110Biological sex: FemaleType: InterventionalSponsor: Instituto de Investigación Sanitaria AragónUpdated: Aug 21, 2026Locations: 1
Eligibility criteria
Aged > 18 years. [+6]
Prior pelvic or abdominal radiation therapy delivered. [+2]